Project Grant R44AI188855
Award Date
12/16/24
Completion Date
5/31/27
Dollars Obligated
$1M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Phagepro, P.b.c. (KHNEFNHKMN84)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Mansfield, MA 02048, USA
Similar Awards
This $173,300 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports Phagepro, P.b.c. (doing business as Phagepro Inc.), a minority-owned, woman-owned small business, in planning for a Phase I/II clinical trial of their Prophylactic-VC (PVC) bacteriophage cocktail intervention to prevent the spread of cholera. The funding will be used to develop necessary clinical trial...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $453,750 to Tufts University School of Medicine to study how certain bacteriophages (viruses that infect bacteria) evade the protective mechanisms of bacteria, including some deadly pathogens like Vibrio cholerae. The project aims to determine the counter-defense mechanisms used by these phages and identify the...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $173,030 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to President and Fellows of Harvard College. The grant, awarded on September 25, 2024, will fund the development of a novel assay for targeted isolation of environmental bacteriophages (phages) based on their receptor dependencies. The project aims to create a generalizable technique that allows selecting phages that require...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,388,838 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Research Foundation For The State University Of New York (RF SUNY) to optimize phage cocktail regimens for treating extensively drug-resistant Pseudomonas aeruginosa. The project aims to: 1) develop a quantification assay for the phage cocktail, 2) identify optimal phage combinations and administration patterns...
This Project Grant award of $427,625.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research by Washington University to discover novel anti-biofilm agents derived from bacteriophages. The goal is to develop alternative therapies for treating biofilm-associated infections, which are a major challenge for pathogens like Pseudomonas aeruginosa. The research will isolate phages that can overcome biofilm barriers,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $479,730 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Wisconsin - Madison. The 5-year grant, effective from December 1, 2024 to November 30, 2029, will support research to elucidate the mechanisms by which prophages (viral DNA) in the gut symbiont Limosilactobacilus reuteri modulate the production of the antimicrobial compound reuterin. The research aims to...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,995 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Xiretsa Inc., a minority-owned small business located in Santa Barbara, CA. The grant will fund the development of a novel class of antimicrobial compounds called Anti-Infective Conjugated Electrolytes (ACEs) that target the bacterial cell membrane to address the growing threat of antimicrobial resistance. The project...
This federal Project Grant award of $779,235, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the molecular mechanisms and consequences of biofilm formation in Vibrio cholerae, the bacterium that causes cholera. The primary awardee, the University of California, Santa Cruz, will conduct research focused on: 1) determining how the bacterial second messenger...
This Project Grant award of $106,446 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855) aims to establish an innovative, high-throughput method for identifying bacteriophages (phages) and their bacterial host cells within complex microbial communities like the human gut microbiome. The principal investigator will adapt a single-cell RNA sequencing (scRNA-seq) protocol to rapidly screen bacterial cells...
This $408,375 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to elucidate phage resistance mechanisms in Mycobacterium abscessus (MAB) and assess how these can be leveraged to enhance the efficacy of antibiotic therapy. The overarching goal is to deepen the fundamental understanding of phage-mycobacteria interactions and apply this knowledge to develop...